represented in the no-GVHD group. As ST2 concentrations differed between conditioning intensities, we used 3 models for prediction using the median ST2 concentrations for UM FIC, UM RIC, and DFCI FIC as cutpoints.
Bronchiolitis obliterans syndrome (BOS) after allogeneic HSCT is associated with high mortality and unknown pathogenesis. We present interim results from a prospective phase II trial evaluating of montelukast for the treatment of BOS after HSCT and studying BOS biology. Montelukast interrupts cysteinyl leukotriene activity and may diminish homing of activated cells to bronchioles and fibrosis. Twentythree patients have enrolled with stable or decreasing immunosuppression for 3 months prior and BOS diagnosed by modified NIH criteria; 2 were withdrawn, and 19 have completed primary endpoint. Participants ranged from 15-72 years, 13/23 female, most had moderate to severe disease with baseline FEV1 of 46% predicted (24-73), and median FEV1/VC 0.5 (0.29-0.78). Montelukast was well-tolerated and no patient required escalation of BOS-directed therapy during the evaluation period. All patients met criteria for treatment success (<15% decline in 6 months), with FEV1 either increased 5-13% of predicted (n¼5), stable (n¼7), or declined 5-13% (n¼6). FEV1 slope of decline was generated using regression line of FEV1 value vs. days post-HSCT. At 6 months, slope was improved in 9 patients, stable in 9, declined in 1. Other manifestations of cGVHD showed: 5/8 GI GVHD improved and 3/8 stable; 5/10 liver cGVHD improved, 4/10 stable, 1 worse, using NIH consensus staging. Survival of the study cohort is 90% (19/21); 2 year survival is 84% (10/12), twice published data (44%). Bronchoalveolar lavage (BAL) from in non-infected patients at baseline revealed cysteinyl leukotriene receptor expression on CD4 and CD8 T cells, granulocytes, and eosinophils, thereby potentially implicating these populations in BOS biology. While blood leukotriene receptor expression on CD4 cells was similar to normal donors, CD4 proportion was significantly reduced in BOS patients (P < 0.01). Other blood receptor levels of these populations were similar between normal donors and controls, although CD8 T cells trended toward decreased receptor expression after treatment at 6 months and decreased proportion of CD8 T cells at 2 years (p<0.04). B cells were absent in BAL while present in blood. These data suggest that: 1) montelukast is a safe and effective therapy for BOS after allogeneic HSCT; 2) T cells, granulocytes, and eosinophils (though not B cells) were associated with BOS in BAL; and 3) cysteinyl leukotrienes may be a point of regulation in the progression of BOS after HSCT. Acute graft-versus-host disease (aGVHD) is primarily a Tcell mediated process. Uric acid released from dying cells acts as a danger signal that alerts the immune system to cell death and promotes cytotoxic T cell responses. Elimination of uric acid in mouse models reduces this immune response. We hypothesized that lower serum uric acid levels at the time of transplant may decrease the incidence of aGVHD. Through record review, we recorded serum uric acid levels from day -7 through day +6 from 43 historical control patients who received myeloablative HCT (MRD, n¼32; MUD, n¼11) at the Massachusetts General Hospital between 2007 and 2010, these patients received standard allopurinol. We also obtained uric acid levels from 23 consecutive patients (19-59 years) with hematologic malignancies in complete remission (AML, n¼13; ALL, n¼8; MDS, n¼1; MPD, n¼1) who were treated in a pilot trial using rasburicase as part of a myeloablative conditioning regimen, followed by GCSF-mobilized HLA-matched (MRD, n¼18; MUD, n¼5) peripheral blood HCT. Urate oxidase (Rasburicase) was administered beginning on the first day of conditioning at a dose of 0.20 mg/kg IV daily for 5 days starting from day -7. GVHD prophylaxis for all patients consisted of cyclosporine or tacrolimus/MTX for MRD transplants and tacrolimus/ MTX/ +/-ATG for MUD transplants. Out of the control group, patients who developed aGVHD (grade 2+) had a similar mean serum uric acid level over all days (2.82 mg/dl) compared to patients who did not have aGVHD (2.86 mg/dl, 2-tailed t-test P ¼ .74, Figure 1A) . Results depend on the type of transplant received, however, as MUD transplants showed a differential expression in serum uric acid levels between the two groups (2.64mg/dl for aGVHD+ vs. 2.18 for aGVHD-, P ¼ .047, Figure 1B) , while MRD transplants did not show a difference (2.97mg/dl for aGVHD+ vs. 2.98 for aGVHD-, P ¼ .95, Figure 1C ). Patients given rasburicase had a lower serum uric acid level compared to the control arm (0.213mg/dl vs. 3.04 for d-7 to -2; 1.20mg/dl vs. 2.85 over all days, P < .0001) as well as significantly less aGVHD (rasburicase: 22% vs. control: 48%, Fisher's exact test, P ¼ .033). Lower serum uric acid level at the time of transplantation appears to be protective against the development of aGVHD among patients receiving matched unrelated donor transplants. Rasburicase, when administered during the conditioning, significantly lowers the serum uric acid level and appears to decrease aGVHD. 
